Before you have the Essure system inserted your health care provider will likely:
- Review the risks and benefits of reversible and permanent methods of contraception
- Ask about your reasons for choosing sterilization and discuss factors that could lead to regret, such as a young age or marital discord
- Explain the details of the procedure
- Discuss the causes and probability of sterilization failure
- Reinforce that the Essure system can't be reversed
- Discuss the need for you to use another method of contraception for three months after the procedure, or until tubal blockage is confirmed
- Help you choose the best time to do the procedure
- Discuss the risks of sexually transmitted infection (STI) and explain the need for condom use if you are at high risk of STI
Your health care provider will need a clear view of your tubal openings to insert the Essure system. He or she may recommend having the procedure done shortly after your period. If your periods are irregular, he or she may recommend using a hormonal contraceptive that contains progestin — such as the combination birth control pill, minipill or contraceptive injection (Depo-Provera) — to thin the lining of your uterus (endometrium).
March 15, 2016
- Hatcher RA, et al. Contraceptive Technology. 20th ed. New York, N.Y.: Ardent Media; 2011:249.
- Greenberg J. Hysteroscopic sterilization. http://www.uptodate.com/home. Accessed Oct. 26, 2014.
- Essure (prescribing information). Milipitus, Calif.: Bayer Healthcare LLC; 2012. http://www.essuremd.com. Accessed Oct. 28, 2014.
- Adelman MR, et al. Management of complications encountered with Essure hysteroscopic sterilization: A systematic review. Journal of Minimally Invasive Gynecology. 2014;21:733.
- Jost S, et al. Essure permanent birth control effectiveness: A seven-year survey. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013;168:134.
- FDA takes additional action to better understand safety of Essure, inform patients of potential risks. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm488313.htm. Accessed March 3, 2016.
- Laughlin-Tommaso SK (expert opinion). Mayo Clinic, Rochester, Minn. March 4, 2016.